[
  {
    "ts": null,
    "headline": "SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU",
    "summary": "Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.",
    "url": "https://finnhub.io/api/news?id=d01dcd7dbef284732e04c0f4383abd6a32c671b8df22f1d3257d57041b5fbd29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758556980,
      "headline": "SNY & REGN's Dupixent Receives CHMP Backing for Urticaria in EU",
      "id": 136848037,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Sanofi/Regeneron's Dupixent wins CHMP backing for chronic spontaneous urticaria in the EU, paving the way for expanded treatment options.",
      "url": "https://finnhub.io/api/news?id=d01dcd7dbef284732e04c0f4383abd6a32c671b8df22f1d3257d57041b5fbd29"
    }
  },
  {
    "ts": null,
    "headline": "Humana initiated, Paycom upgraded: Wall Street's top analyst calls",
    "summary": "Humana initiated, Paycom upgraded: Wall Street's top analyst calls",
    "url": "https://finnhub.io/api/news?id=2abde970f1ee708b93bab11f6f91e1c8ed804094855d0d558ad90ee2c3641063",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758548112,
      "headline": "Humana initiated, Paycom upgraded: Wall Street's top analyst calls",
      "id": 136848446,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Humana initiated, Paycom upgraded: Wall Street's top analyst calls",
      "url": "https://finnhub.io/api/news?id=2abde970f1ee708b93bab11f6f91e1c8ed804094855d0d558ad90ee2c3641063"
    }
  },
  {
    "ts": null,
    "headline": "Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion",
    "summary": "Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the European Union (EU) TARRYTOWN, N.Y. and PARIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)",
    "url": "https://finnhub.io/api/news?id=a15ca55e0c5cf8be6b5225a2ccbada61f5c00368179b070a3a577978fa148c86",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758515340,
      "headline": "Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion",
      "id": 136851369,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo If approved, Dupixent would be the first targeted medicine in over a decade indicated for CSU in the European Union (EU) TARRYTOWN, N.Y. and PARIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP)",
      "url": "https://finnhub.io/api/news?id=a15ca55e0c5cf8be6b5225a2ccbada61f5c00368179b070a3a577978fa148c86"
    }
  },
  {
    "ts": null,
    "headline": "Sanofi Sees Progress for Hives Treatment in EU, Longer U.S. Review for MS Drug",
    "summary": "Sanofi Sees Progress for Hives Treatment in EU, Longer U.S. Review for MS Drug",
    "url": "https://finnhub.io/api/news?id=d60db951b38ef6e9d2863b2950d742725c42d1697e8983b6141db8bdea881566",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758509160,
      "headline": "Sanofi Sees Progress for Hives Treatment in EU, Longer U.S. Review for MS Drug",
      "id": 136872926,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Sanofi Sees Progress for Hives Treatment in EU, Longer U.S. Review for MS Drug",
      "url": "https://finnhub.io/api/news?id=d60db951b38ef6e9d2863b2950d742725c42d1697e8983b6141db8bdea881566"
    }
  }
]